Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports

Objective To follow up on previously reported associations between periconceptional use of selective serotonin reuptake inhibitors (SSRIs) and specific birth defects using an expanded dataset from the National Birth Defects Prevention Study. Design Bayesian analysis combining results from independent published analyses with data from a multicenter population based case-control study of birth defects. Setting 10 centers in the United States. Participants 17 952 mothers of infants with birth defects and 9857 mothers of infants without birth defects, identified through birth certificates or birth hospitals, with estimated dates of delivery between 1997 and 2009. Exposures Citalopram, escitalopram, fluoxetine, paroxetine, or sertraline use in the month before through the third month of pregnancy. Posterior odds ratio estimates were adjusted to account for maternal race/ethnicity, education, smoking, and prepregnancy obesity. Main outcome measure 14 birth defects categories that had associations with SSRIs reported in the literature. Results Sertraline was the most commonly reported SSRI, but none of the five previously reported birth defects associations with sertraline was confirmed. For nine previously reported associations between maternal SSRI use and birth defect in infants, findings were consistent with no association. High posterior odds ratios excluding the null value were observed for five birth defects with paroxetine (anencephaly 3.2, 95% credible interval 1.6 to 6.2; atrial septal defects 1.8, 1.1 to 3.0; right ventricular outflow tract obstruction defects 2.4, 1.4 to 3.9; gastroschisis 2.5, 1.2 to 4.8; and omphalocele 3.5, 1.3 to 8.0) and for two defects with fluoxetine (right ventricular outflow tract obstruction defects 2.0, 1.4 to 3.1 and craniosynostosis 1.9, 1.1 to 3.0). Conclusions These data provide reassuring evidence for some SSRIs but suggest that some birth defects occur 2-3.5 times more frequently among the infants of women treated with paroxetine or fluoxetine early in pregnancy.

[1]  L D Edmonds,et al.  The National Birth Defects Prevention Study , 2001, Public health reports.

[2]  K R Abrams,et al.  Bayesian methods in meta-analysis and evidence synthesis. , 2001, Statistical methods in medical research.

[3]  R. Kirby,et al.  Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[4]  J. Goodman,et al.  Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. , 2009, Birth.

[5]  David J. Lunn,et al.  The BUGS Book: A Practical Introduction to Bayesian Analysis , 2013 .

[6]  A. Scialli,et al.  Teratogenic exposures , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[7]  A. Olshan,et al.  The National Birth Defects Prevention Study: A review of the methods. , 2015, Birth defects research. Part A, Clinical and molecular teratology.

[8]  S. Hernández-Díaz,et al.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.

[9]  Lilah M. Besser,et al.  Diabetes mellitus and birth defects. , 2008, American journal of obstetrics and gynecology.

[10]  B. Källén,et al.  Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data , 2010, Psychological Medicine.

[11]  A. Abuhamad,et al.  ACOG Practice Bulletin, clinical management guidelines for obstetrician-gynecologists number 98, October 2008 (replaces Practice Bulletin number 58, December 2004). Ultrasonography in pregnancy. , 2008, Obstetrics and gynecology.

[12]  I. Wilson,et al.  Antidepressant Use: Concordance Between Self-Report and Claims Records , 2003, Medical care.

[13]  Meghan T. Frey,et al.  Prevalence of Prescription Medication Use Among Non-pregnant Women of Childbearing Age and Pregnant Women in the United States: NHANES, 1999–2006 , 2015, Maternal and Child Health Journal.

[14]  R. Lowry,et al.  Folic acid fortification and the birth prevalence of congenital heart defect cases in Alberta, Canada. , 2013, Birth defects research. Part A, Clinical and molecular teratology.

[15]  M. Nørgaard,et al.  Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis , 2010, Clinical epidemiology.

[16]  Jan M Friedman,et al.  Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. , 2007, The New England journal of medicine.

[17]  M. Gissler,et al.  Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design , 2015, BMJ : British Medical Journal.

[18]  T. Woodruff,et al.  Evaluating the health significance of hazardous air pollutants using monitoring data. , 2001, Public health reports.

[19]  I. Anderson,et al.  Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors , 1999, Drugs.

[20]  S. Rasmussen,et al.  Guidelines for case classification for the National Birth Defects Prevention Study. , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[21]  S. Rasmussen,et al.  Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. , 2006, The New England journal of medicine.

[22]  I. Petersen,et al.  Selective serotonin reuptake inhibitors and risk for major congenital anomalies. , 2012, Obstetrics and gynecology.

[23]  Mary K. Kowal,et al.  National trends in antidepressant medication treatment among publicly insured pregnant women. , 2013, General hospital psychiatry.

[24]  P. Hallberg,et al.  Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. , 2006, The New England journal of medicine.

[25]  A. Olshan,et al.  First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. , 2010, Birth defects research. Part A, Clinical and molecular teratology.

[26]  T. Sadler.  Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. , 2011, Reproductive toxicology.

[27]  Cosma Rohilla Shalizi,et al.  Philosophy and the practice of Bayesian statistics. , 2010, The British journal of mathematical and statistical psychology.

[28]  S. Gentile.  Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects , 2011, Acta psychiatrica Scandinavica.

[29]  Wilhelmina S Kerstjens-Frederikse,et al.  First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. , 2009, Birth defects research. Part A, Clinical and molecular teratology.

[30]  S. Shapiro,et al.  Effect of questionnaire design on recall of drug exposure in pregnancy. , 1986, American journal of epidemiology.

[31]  B. Ottesen,et al.  Ultrasonography in pregnancy , 1994, Ugeskrift for laeger.

[32]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[33]  S. Rasmussen,et al.  Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population , 2011, Journal of clinical pharmacology.